The molecule a drug grabs
A drug target is the specific biological molecule — almost always a protein, sometimes a nucleic acid — that a drug physically binds in order to change what happens in the body. A drug is not a magic dust that floats around fixing things; it is a small object that fits into a particular pocket on a particular molecule, like a key into a lock. When it sits there, it nudges that molecule to behave differently, and that change is the medicine's effect.
The way a drug changes its target is called the mechanism of action. For example, a painkiller might block an enzyme that makes pain signals, while a blood-pressure drug might switch off a receptor that tells blood vessels to tighten. Different drug, different target, different mechanism — but the shape of the story is always the same: bind a molecule, change its job, change the biology.
Binding happens in a pocket
The drug does not stick to the whole target — it settles into a dent or cleft on the surface called a binding pocket. A good pocket is roughly the size and shape of a small drug molecule and is lined with atoms that can form gentle, specific contacts. How tightly the drug holds on is its affinity: high affinity means it clings even when present at very low concentration, which is usually what we want so the dose can be small.
When a drug acts the way it was designed to on its intended target, we call that the on-target effect — the result we actually wanted. (Later in this track and in other tracks you'll meet the unwanted twin, the off-target effect, where a drug accidentally binds something else.) For now, hold this picture: a small molecule, a pocket, a grip, and a changed job.
Why the target is everything
Choosing the right target is the most consequential decision in a drug project. A beautiful molecule aimed at the wrong target cures nothing; an average molecule aimed at the right target can be transformative. That is why teams spend years on target validation — building evidence that changing this molecule really will change the disease — before pouring effort into chemistry. The rest of this track tours the great families of targets so you can recognise each one and sense what kind of drug it invites.